Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

We conducted a double-blind, placebo-controlled, parallel, dose-escalation trial to evaluate the pharmacokinetics and safety of single, oral doses of amprenavir (141W94; formerly VX-478), a potent inhibitor of human immunodeficiency virus (HIV) type 1 protease, administered as hard gelatin capsules...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Sadler, Brian M., Hanson, Cynthia D., Chittick, Gregory E., Symonds, William T., Roskell, Neil S.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 1999
Teme:
Antiviral Agents
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC89344/
https://ncbi.nlm.nih.gov/pubmed/10390223
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki